Dina Elmonshed's questions to Moderna Inc (MRNA) leadership • Q1 2025
Question
Dina Elmonshed, on for Michael Yee, asked for Moderna's perspective on a media report suggesting future vaccine trials would require a placebo control and the potential impact on trial enrollment.
Answer
President Stephen Hoge declined to comment on unconfirmed policy changes but noted that many of Moderna's pivotal trials, including for COVID, RSV, CMV, and norovirus, were already placebo-controlled. He emphasized the company's commitment to providing whatever data regulators and public health officials require to support their products.